Please assess the completion status of the following clinical trial:

Trial Title: Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Any self-declared ethno-racial category.~* Medically healthy subjects.~* Subjects with two healthy eyes.~* Intraocular pressure (IOP) less than 22 mmHg in each eye.~* Best-corrected visual acuity (BCVA) in each eye 20/50 or better.~* Open angles in both eyes.~* Contact lens wear stopped at least 3 days prior to study, and during the study.~* Ability to cooperate for examinations required for study.~Exclusion Criteria:~* Chronic or acute ophthalmic diseases including glaucoma, wet type macular degeneration, uveitis and clinically significant cataract.~* Evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis.~* Cornea pathologic changes preventing reliable measurement.~* Narrow anterior chamber angle.~* Previous intraocular surgeries, laser procedures, and intravitreal injections.~* Previous corneal refractive surgeries.~* Myopia greater than -6.00 D spherical equivalent.~* Hyperopia greater than +2.00 D spherical equivalent.~* Lack of suitable episcleral vein for measurement.~* Ocular trauma within the past 6 months.~* Ocular infection or ocular inflammation in the past 3 months.~* Ocular medication of any kind within 30 days of study visit.~* Known hypersensitivity to Phenylephrine or topical anesthetic medication.~* Severe hypertension: Systolic blood pressure greater than 180 mmHg and/or diastolic blood pressure greater than 105 mmHg.~* A known history of ischemic heart disease (angina or myocardial infarction), cerebrovascular accidents, cardiac arrhythmias, cerebral or aortic aneurysms.~* Uncontrolled diabetes mellitus.~* Uncontrolled hyperthyroidism.~* Use of some systemic medications within 30 days prior to study including: β-adrenergic antagonists, α-adrenergic agonists and antagonists, calcium channel blockers, diuretics, vasodilators, monoamine oxidase inhibitors, and systemic steroids.~* Participation in any interventional study within the past 30 days prior to study visit.~* Women who are pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Phenylephrine (Type: EXPERIMENTAL): Subjects will receive topical phenylephrine 2.5% eye drop instilled in one eye after all baseline measurements.

Based on this trial design, predict the completion outcome and termination type (if applicable).